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Herpes simplex virus type 1 (HSV-1) is one of the most common causes of sporadic encephalitis. The initial
clinical course of HSV encephalitis (HSE) is highly variable, and the infection may be rapidly fatal. For
effective treatment with antiviral medication, an early diagnosis of HSE is crucial. Subtle brain infections with
HSV may be causally related to neuropsychiatric disorders such as Alzheimer’s dementia. We investigated the
feasibility of a noninvasive positron emission tomography (PET) imaging technique using [18F]FHPG as a
tracer for the detection of HSE. For this purpose, rats received HSV-1 (infected group) or phosphate-buffered
saline (control group) by intranasal application, and dynamic PET scans were acquired. In addition, the
distribution of tracer accumulation in specific brain areas was studied with phosphor storage imaging. The
PET images revealed that the overall brain uptake of [18F]FHPG was significantly higher for the infected group
than for control animals. Phosphor storage images showed an enhanced accumulation of [18F]FHPG in
regions known to be affected after intranasal infection with HSV. High-performance liquid chromatography
metabolite analysis showed phosphorylated metabolites of [18F]FHPG in infected brains, proving that the
increased [18F]FHPG uptake in infected brains was due to HSV thymidine kinase-mediated trapping. Freeze
lesion experiments showed that damage to the blood-brain barrier could in principle induce elevated [18F]
FHPG uptake, but this nonspecific tracer uptake could easily be discriminated from HSE-derived uptake by
differences in the tracer kinetics. Our results show that [18F]FHPG PET is a promising tool for the detection
of HSV encephalitis.
Herpes simplex virus (HSV) is the most commonly recog-
nized cause of acute sporadic encephalitis in humans in the
Western world (19, 29, 33). Encephalitis is an acute and life-
threatening infection of the brain parenchyma. If left un-
treated, HSV encephalitis (HSE) has an extremely high mor-
tality rate of about 70%, with 3% of survivors regaining
normal function. The exact incidence of HSE is not known, but
it has been estimated to occur in approximately one to three
individuals per million per year (19, 30). Approximately one-
third of the patients that develop HSE are younger than 20
years of age, and 50% of the people who have HSE are older
than 50 years of age (35).
Primary infection with HSV type 1 (HSV-1) usually occurs in
the oropharyngeal mucosa. The primary infection usually is
asymptomatic but can cause gingivostomatitis, pharyngitis, or
respiratory disease (18). After the primary infection, HSV-1 is
transported by transneuronal spread along a division of the
trigeminal nerve. The virus then establishes latency in the
trigeminal ganglion. The reactivation of a latent ganglionic
infection with replication of the virus usually leads to cold
sores (19). Sporadic anterograde transport from the ganglion
may cause viral encephalitis with infection in the temporal
cortex and limbic system structures (19, 29). The reactivation
of latent HSV-1 can occur spontaneously or following various
stimulating events. A variety of factors, such as stress, UV
light, hormones, surgery, and radiotherapy, may play a role in
the reactivation process of herpes simplex virus (28). The clin-
ical presentation of HSE includes headache, fever, confusion,
an altered level of consciousness, and sometimes psychosis as
early signs (19, 23, 36). In the research field of Alzheimer’s
dementia, there is growing evidence supporting the hypothesis
that the disease is in some instances related to a subtle en-
cephalitic response to HSV-1 in the brain (16). Elevated anti-
bodies against HSV-1 predict attenuated memory deficits in
patients with schizophrenia (10), potentially due to brain acti-
vation of HSV-1.
The diagnosis of HSE is usually established by a combina-
tion of clinical and investigative features. The gold standard for
diagnosing HSE has been the isolation of HSV from brain
tissue. However, because of the risk of complications of brain
biopsy, this diagnostic approach has never gained wide accep-
tance (26). In clinical practice, brain biopsies have been re-
placed with examinations of the cerebrospinal fluid (CSF),
electroencephalography (EEG), and magnetic resonance im-
aging (MRI) (19, 20, 29). At present, MRI is the imaging
method of choice for HSE because it provides the most sensi-
tive method for detecting early lesions. The MRI scan may,
however, be normal early in the infection (19, 29). During the
acute stage of HSE, EEG generally shows various abnormali-
ties, but when the acute phase is over, the EEG can become
normal. A meta-analysis revealed that the sensitivity of EEG
for the diagnosis of HSE is 86% and 100% for adults and
neonates, respectively. The EEG abnormalities, however, are
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not specific to HSE, and thus, a confirmation of HSE by other
methods is required (21). A CSF examination generally dem-
onstrates elevations in protein concentrations and lymphocytic
pleocytosis. Red blood cells are frequently (84%) seen as well.
However, these changes are not specific to HSE, and normal
CSF findings can appear during early disease. CSF viral cul-
tures for HSV-1 are negative in95% of cases. Elevated levels
of antibodies to HSV are not seen in the CSF until 10 days to
2 weeks after the onset of disease (22).
The application of PCR to detect HSV DNA in the CSF has
made a substantial contribution to the diagnosis of HSE. HSV
PCR is a very sensitive method for the diagnosis of HSE, but
the test may be negative during the first 24 to 48 h and after 10
days of symptoms (19, 29).
The drug of choice for the treatment of HSE is the nucleo-
side analogue acyclovir (ACV). ACV selectively inhibits the
HSV-specific DNA polymerase and is activated specifically in
HSV-infected cells, which express the HSV thymidine kinase
(HSVtk) enzyme. The standard dose of ACV is 10 mg/kg of
body weight three times daily for 14 days (19). For the suc-
cessful treatment of HSE, therapy with ACV should be initi-
ated early, as soon as the diagnosis of HSE is suspected (34).
An early and accurate diagnosis of HSE is critical for the
successful management of HSE.
We aim to develop a noninvasive tool to detect HSV en-
cephalitis by using positron emission tomography (PET) imag-
ing. For this purpose, we investigated the feasibility of using
9-[(1-[18F]fluoro-3-hydroxy-2-propoxy)methyl]guanine ([18F]
FHPG) as the virus tracer. [18F]FHPG is a derivative of gan-
ciclovir, in which one hydroxyl group is replaced with a radio-
active fluorine atom. [18F]FHPG is selectively phosphorylated
by the HSVtk enzyme. Phosphorylated [18F]FHPG metabolites
are selectively trapped within infected cells and can be moni-
tored with PET. PET imaging with this tracer has proven to be
successful for the detection of HSVtk-expressing C6 glioma
cells outside the brain (14). Whether this tracer can also detect
HSVtk in the HSV-infected brain is still unknown. For this
study, we investigated the feasibility of the [18F]FHPG PET
technique for virus detection in an animal model of HSE. In
this model, rats are inoculated intranasally with HSV-1. The
virus has access to nervous tissue in a noninvasive manner via
the olfactory pathway. Seven days after inoculation, viral rep-
lication is mainly observed in the brain, spinal cord, and gan-
glia (12). The viral spread in this model mimics an important
route of viral infection for human HSE (11).
MATERIALS AND METHODS
Chemicals. Medetomidine (Domitor; 10 mg/ml) was obtained from Pfizer
(New York, N.Y.), and ketamine (Ketanest; 25 mg/ml) was obtained from Parke-
Davis (Munich, Germany).
Preparation of [18F]FHPG. [18F]FHPG was prepared as described by Alaud-
din et al. (1), with only minor modifications. The fluorination reaction was
carried out at 125°C for 30 min and the subsequent hydrolysis was performed at
90°C for 5 min. The reaction mixture was neutralized by the addition of a sodium
phosphate buffer (pH 7.2) prior to purification by high-performance liquid chro-
matography (HPLC), which was performed over a semipreparative Alltima C18
reverse-phase column (5 m by 10 mm by 250 mm; Alltech, Deerfield, Ill.), with
3% ethanol–10 mM NaH2PO4 in saline as the eluent (flow rate, 5 ml/min;
retention time, 16 min). The radiochemical yield was 5 to 15% (corrected for
decay), and the radiochemical purity was 99% (HPLC was done with a Nova
Pak C18 column [3 m by 9 mm by 150 mm] with 2% acetonitrile; flow rate, 1
ml/min; retention time, 6 min).
Animal model. Male outbred WU (Wistar-Unilever) rats (6 to 8 weeks old)
were obtained from the breeding colony of the National Institute for Public
Health, Bilthoven, The Netherlands, or from Harlan, The Netherlands. The
animals were housed separately in Macrolon cages and were provided with
commercial rat chow (Hope Farms, Woerden, The Netherlands) and tap water
ad libitum.
Infected group. Rats were infected intranasally with HSV-1. The HSV strain
used for this study was a clinical isolate of a type 1 virus and was cultured in Vero
cells and assayed for PFU per milliliter as described previously (12). Rats were
anesthetized with ether and infected by the application of 100 l of phosphate-
buffered saline (PBS) containing 107 PFU of virus on the nostrils (50 l per
nostril). Sickness and behavior were scored daily.
Control group. Control animals were treated similarly, except that 100 l of
PBS without virus was applied (12).
Freeze lesion group. To investigate whether [18F]FHPG PET could discrimi-
nate between HSV-1 infection and nonspecific damage to the blood-brain bar-
rier, we performed freeze lesion experiments. Approximately 2 h before the PET
study, rats were anesthetized with an intraperitoneal injection of a mixture of 25
mg/ml ketamine and 1 mg/ml medetomidine (5:1; 1 ml/kg). A skin flap was raised
and a 5-mm trephination in the skull was made to expose the brain. Through the
trephination, a freeze injury was produced by sequential 20- to 60-s applications
of solid carbon dioxide powder (81°C) to the dura overlying the right cerebral
cortex (13). After the freeze lesion was produced, a 1-ml intravenous injection of
Evans blue solution (2% in saline) was given to confirm the disruption of the
blood-brain barrier.
All studies were carried out in compliance with the local ethical guidelines for
animal experiments. The protocols were approved by the local animal ethics
committee.
Viral load. For validation of our HSE model, HSV-1 titers in homogenized
brains from infected animals were determined by a standard plaque assay, as
previously described by Howie et al. (15). For groups of 20 rats each, the
incidence of clinical symptoms was scored independent of the nature of the
symptoms and correlated with the average viral load for the group.
PET studies. Seven days after inoculation of the rats with HSV-1 or PBS or 2 h
after the application of a freeze lesion, dynamic PET scans were acquired. PET
studies were performed by using a Siemens Exact HR positron camera (Sie-
mens/CTI, Knoxville, Tenn.) with a resolution of about 5 mm (FWMH). Trans-
mission and emission scans were obtained in the two-dimensional mode. The rats
were anesthetized with an intraperitoneal injection of a mixture of 25 mg/ml
ketamine and 1 mg/ml medetomidine (5:1; 1 ml/kg) and then were positioned in
the PET camera with their long axis parallel to the transaxial plane of the
tomograph in order to obtain sagittal sections. A transmission scan was obtained
to correct for the attenuation of 511 keV of photons by tissue. An H215O PET
scan was performed for anatomical localization of the brain. At least 15 min after
the H215O PET data acquisition was completed, 18.8  14.2 MBq of [18F]FHPG
was injected into the tail vein. Data were acquired for 1 h. Data analysis was
performed with Siemens ECAT 7.1 software. In the images of the last frame of
the H215O PET scan, regions of interest were drawn around the rat brain in the
planes where the brain was clearly visible. These regions of interest were copied
to the [18F]FHPG emission images, and time-activity curves were calculated.
Tracer accumulation is expressed as the percentage of the injected dose per gram
of tissue (%ID/g). Statistical analysis was performed by using the two-sided
unpaired Student t test. Significance was reached when the P value was 0.05.
After the PET scan, the rats were sacrificed by extirpation of the heart. The
brain was either dissected and frozen in isopentane at 80°C for autoradiogra-
phy purposes or dissected and homogenized for HPLC metabolite analysis and
PCR analysis.
Autoradiography. The accumulation of [18F]FHPG in specific brain areas was
visualized by phosphor storage imaging. Frozen brain slices of 80-m thickness
were prepared with a Cryo-cut microtome (model 840; American Optical Corp.,
Buffalo, N.Y.) at 7°C. The slices were placed on object glasses and dried at
room temperature. A Cyclone (multipurpose; Packard Instrument Company,
Inc., Meriden, Conn.) storage phosphor screen was exposed to the brain slices for
at least 36 h (20 half-lives of 18F). The phosphor screen was analyzed with
Optiquant analysis software (version 03.00; Packard Instrument Company, Inc.,
Meriden, Conn.). A calibration line was made during each experiment to convert
the digital light units of the exposed screen into becquerels.
Regions of interest were drawn bilaterally over the nuclei olfactorius, the
motor cortex, the somatosensory cortex, and the substantia nigra. The radioac-
tivity in each area was quantified with the aid of the calibration line and was
corrected for the injected dose of [18F]FHPG and the tissue volume. Tracer
uptake is expressed as the percentage of the injected dose (ID) per volume (ml)
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of tissue. Statistical analysis was performed by using the two-sided unpaired
Student t test. P values of 0.05 were considered significant.
Metabolite analysis. Metabolite analysis was performed by HPLC to deter-
mine the presence of phosphorylated [18F]FHPG metabolites. Brain tissue was
homogenized in 1 ml of a 2% HClO4 solution. The homogenate was centrifuged
(3 min, 5,400 rpm), and the pellet was washed once with 1 ml and twice with 0.5
ml of 2% HClO4. The radioactivity in the acid-soluble and acid-insoluble frac-
tions was measured with a gamma counter. The acid-soluble fraction of the brain
tissue was neutralized with 100 g NaHCO3, centrifuged (3 min, 5,400 rpm), and
analyzed by reverse-phase HPLC (Alphabond C18 column [10 m by 7.8 mm by
300 mm]; eluent, 4% ethanol; flow rate, 1.0 ml/min). The eluate was collected in
fractions of 0.5 ml during a 45-min period and counted in a gamma counter. All
radioactivity injected onto the HPLC column was recovered in the eluate.
HSV PCR. PCR analysis was performed with brain tissues from HSV-infected
rats to confirm the presence of HSV-1. After the PET scan, a sample of the brain
homogenate (as described above) was taken and DNAs were extracted from 100
l of the homogenate by use of a MagnaPure total nucleic acid extraction kit.
Real-time PCRs were performed with 5-l DNA extracts in total volumes of 25
l of universal master mix (Applied Biosystems), using TaqMan probes and the
ABI Prism 7700 sequence detection system. A standard amplification protocol
was used, consisting of 2 min at 50°C for the AmpErase uracil-N-glycosylase step,
10 min at 95°C for the activation of AmpliTaq Gold DNA polymerase, and 40
cycles of 15 s at 95°C and 1 min at 60°C. Type-common primers and probes
selected from the gene coding for glycoprotein D were used for screening. When
the HSV PCR was positive, the subtype was determined by real-time PCR using
type-specific primers and probes, which reacted with a type-specific region of the
gD gene (HSV-1) or the gG gene (HSV-2). The primers and probes were
selected with Primer Express 2.0 and had the following sequences: HSV-1/2
primer 1, 5-GCC GTC AGC GAG GAT AAC C; HSV-1/2 primer 2, 5-GCT
CGG TGC TCC AGG ATA AA; HSV-1/2 probe, 5-FAM-CAC GTA CCT
GCG GCT CGT GAA GAT AAA C-TAMRA; HSV-1 primer 1, 5-TCC TSG
TTC CTM ACK GCC TCCC; HSV-1 primer 2, 5-GCA GIC AYA CGT AAC
GCA CGC T; HSV-1 probe, 5-FAM-CGT CTG GAC CAA CCG CCA CAC
AGG T-TAMRA; HSV-2 primer 1, 5-CGC CCA ATA CGC CTT AGC A;
HSV-2 primer 2, 5-GAG GTT CTT CCC GCG AAA T; and HSV-2 probe,
5-FAM-CTC GCT TAA GAT GGC CGA TCC CAA TC-TAMRA.
RESULTS
Clinical symptoms. In groups of 20 rats each, the numbers of
animals that showed any clinical symptom (irrespective of its
nature) were scored until 7 days after infection. The incidence
of clinical symptoms for each group correlated well with the
average viral load in the brain (Fig. 1).
The first clinical signs of infection were seen on day 5 after
HSV-1 infection. The severities of the clinical symptoms varied
between individual animals and were categorized as follows: 0,
no symptoms; I, redness, swelling, and contamination of the
nose and eyes; II, behavioral signs such as stress or lethargy;
III, severe neurological signs such as impairment of motor
function and paralysis; and IV, death or termination due to
ethical reasons. The incidences of these symptoms after HSV-1
infection are shown in Fig. 2. All animals in the control group
appeared healthy. Scores for rats from other studies, which
were treated similarly with the HSV-1 virus, were also included
in the clinical scores.
All brain samples from HSV-1-infected rats tested positive
by HSV-1 PCR and negative by HSV-2 PCR. These results
confirmed that HSV disseminates to the brain after intranasal
inoculation.
PET studies with HSV-1-infected and control rats. PET
studies were performed with the HSV-1-infected group (n 8)
and the control group (n  3). The PET images revealed that
the overall brain uptake of [18F]FHPG was clearly elevated for
the infected group. Average time-activity curves are shown in
Fig. 3. In the control animals, the initial [18F]FHPG uptake
was rapidly and completely washed out of the brain within 1 h.
In the infected animals, the initial cerebral [18F]FHPG uptake
was a little higher than that in control animals, and trapping of
activity in the brain was observed. After 1 h, the average tracer
uptake was 6.8 	 102  3.2 	 102 %ID/g for the infected
group versus 0.36 	 102  1.1 	 102 %ID/g for the control
group. The difference in tracer uptake in the brain between
control rats and infected rats was statistically significant start-
ing 17.5 min after tracer injection (P  0.05).
An experimental observation that deserves separate atten-
tion is the fact that within the infected group, one animal did
not show any clinical signs of infection (category 0). The tracer
uptake in the brain of this animal was 0.83 	 102 %ID/g, as
FIG. 1. Correlation between the incidence of clinical symptoms
and the viral load in the brains of rats that were intranasally infected
with HSV-1 7 days previously. Each dot in the graph represents the
result for a group of 20 animals (y  0.20x  0.57; r2  0.59; P 
0.0013).
FIG. 2. Clinical symptoms in HSV-infected rats on day 7 after
HSV-1 infection. The clinical symptoms were categorized and the
percent incidence per category was calculated. 0, no symptoms; I,
redness, swelling, and contamination of the nose and eyes; II, behav-
ioral signs such as stress or lethargy; III, severe neurological signs such
as impairment of motor function and paralysis; IV, death or termina-
tion.
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determined by PET, which was within the range of the tracer
uptake in the brains of animals in the control group. The
phosphor storage images of this animal showed only back-
ground activity levels, which were comparable to those of con-
trols. All of the remaining infected rats with clinical symptoms
of HSE showed uptakes of [18F]FHPG above baseline levels.
Autoradiography. The resolution of our clinical PET camera
did not allow us to discriminate between different areas in the
brain. Therefore, the distributions of the virus in specific brain
areas in the infected group and in the control group were
studied by phosphor storage imaging. The phosphor storage
images showed that [18F]FHPG predominantly accumulated
bilaterally in the nuclei olfactorius, the motor cortex, the so-
matosensory cortex, and the substantia nigra. In Fig. 4, the
[18F]FHPG uptake in these regions is shown in a phosphor
image of a control rat brain and a rat brain with severe HSV
infection. The average [18F]FHPG uptake in each region is
shown in Table 1 (n 6 for the nuclei olfactorius and n 7 for
the remaining regions). These data represent the average
[18F]FHPG uptakes in the left and right hemispheres. In the
infected brain, the [18F]FHPG uptakes in the olfactorius, mo-
tor cortex, somatosensory cortex, and substantia nigra were
3.2, 2.2, 2.1, and 1.8 times higher, respectively, than those in
the control brain. These differences in tracer uptake did not
reach statistical significance because of the large variability in
regional tracer uptake between individual animals in the in-
fected group. This variability might be due to different migra-
tion routes of the virus through the brain, resulting in differ-
ences in the regional severity of infection between individual
animals.
Metabolite analysis. To investigate whether [18F]FHPG up-
take in the brain was specifically due to HSV infection, we
performed a metabolite analysis with infected brain tissue and
control brain tissue. The acid-soluble fraction of the brain
tissue was analyzed by reverse-phase HPLC at 1 h postinjec-
tion. In control brain tissue, 96% of the radioactivity in the
acid-soluble fraction consisted of unmetabolized [18F]FHPG.
In HSV-infected brain tissue, approximately 15% polar metab-
olites were found (Fig. 5).
Freeze lesion experiments. To investigate whether [18F]
FHPG PET could discriminate between HSE and nonspecific
damage to the blood-brain barrier, we performed freeze lesion
experiments. Approximately 2 h after the application of a
freeze lesion, dynamic PET scans were acquired. After 1 h, the
tracer uptake was 4.0 	 102  1.2 	 102 %ID/g. Figure 6
shows a time-activity curve for the rats in the freeze lesion
group (n  4). For comparison, the time-activity curves for the
infected and control groups are included. The curves were
vertically translated until the maximum [18F]FHPG activities
were superimposed. From these normalized time-activity
curves, differences in the tracer kinetics are obvious. After 1 h,
the curve for the infected group reached a plateau, whereas the
FIG. 3. Time-activity curves of [18F]FHPG accumulation (%ID/g)
in the brains of control rats and HSV-1-infected rats.
FIG. 4. Phosphor storage images of [18F]FHPG uptake in control rat brain and rat brain with severe HSV-1 infection.
TABLE 1. [18F]FHPG accumulation in some specified brain




HSV group Control group
Olfactorius 0.0213 0.0174 0.0067  0.0006 0.068
Motor cortex 0.0168 0.0103 0.0077  0.0005 0.059
Somatosensory cortex 0.0146 0.0080 0.0070  0.0032 0.164
Substantia nigra 0.0137  0.0056 0.0075  0.0035 0.122
a Results are means  standard deviations.
7724 BUURSMA ET AL. J. VIROL.
 o
n







[18F]FHPG activities in the brains of animals in the freeze
lesion and control groups still strongly decreased. The radio-
activity was rapidly washed out for the freeze lesion group, and
the decline in [18F]FHPG activity was comparable to that for
the control group. However, the initial tracer uptake in the
brains of animals with freeze lesions was higher than that for
the control group. These results suggest that a freeze lesion
leads to a high initial [18F]FHPG uptake caused by more per-
fusion of the brain tissue and that no trapping of radioactivity
occurs.
DISCUSSION
The aim of this study was to explore whether [18F]FHPG
PET could be a suitable method to detect HSV in the “en-
cephalitic” brain. The HSV-encoded protein thymidine kinase
(HSVtk) is one of the viral genomic elements that have been
associated with neurovirulence (4). It plays an important role
in HSV pathogenesis and appears to be necessary for reacti-
vation from latency (8). A tk-deficient mutant of an HSV-1
strain caused decreased neurovirulence in a mouse model of
HSV-1-induced encephalitis (7). tk mRNA transcription oc-
curs at an early stage of HSV-1 infection: in explanted trigem-
inal ganglia removed from rabbits with previously established
latency, the tk mRNA appeared in culture as early as 8 h after
the start of incubation (27). Because of the aforementioned
characteristics, HSVtk expression could be a target for imaging
of HSE early after the onset of the disease. Previously, we have
shown that HSVtk expression can be monitored in a double-
tumor-bearing rat model by the use of [18F]FHPG PET (14).
Whether [18F]FHPG PET can detect HSVtk inside the brain
remained to be investigated. In a pharmacokinetic modeling
study, the [18F]FHPG PET signal correlated well with the
percentage of HSVtk-expressing cells (9). In addition, we re-
ported that FHPG resembles ACV in its transport across the
cell membrane and its phosphorylation characteristics (5).
Therefore, we suggested that [18F]FHPG PET might be suit-
able for determining ACV’s pharmacokinetics, which would
allow for prediction of the treatment outcome for herpes-
related diseases. This would be useful for HSE, which is
treated with high doses of ACV.
For this study, the accumulation of [18F]FHPG was exam-
ined in the brains of intranasally HSV-infected rats. Previously,
intranasal inoculation in a mouse model resulted in infection
of brain regions that are also involved in the human disease,
such as structures of the limbic system (31).
The present PET studies with [18F]FHPG showed an en-
hanced accumulation of the tracer in the brains of HSV-in-
fected rats compared to brains of uninfected rats. Phosphor
storage images showed that the accumulation of [18F]FHPG
was enhanced in subregions known to be affected after intra-
nasal infection with HSV, such as the olfactory nuclei (31).
The elevated [18F]FHPG uptake in the infected rats was
supposed to be due to the trapping of [18F]FHPG metabolites
within infected cells as a result of selective phosphorylation of
the tracer by the HSVtk enzyme. This was confirmed by a
metabolite analysis of HSV-infected brain tissue and control
brain tissue. In control brain tissue, almost all radioactivity
represented the parent compound. In HSV-infected brain tis-
sue, not only unmetabolized FHPG but also phosphorylated
metabolites were found, which accounted for approximately
15% of the radioactivity. To comprehend the large amount of
unmetabolized [18F]FHPG in the infected brain homogenate,
one should take into account that the majority of unmetabo-
lized radioactivity in the brain was located in the blood com-
partment, whereas the metabolized fraction was located within
brain cells. In a previous study, we demonstrated that all of the
radioactivity in plasma consisted of an unmetabolized tracer
(14). In addition, the phosphor storage imaging studies showed
that the infection was restricted to specific small brain regions.
In these regions, the elevated radioactivity represented the
FIG. 5. [18F]FHPG metabolite analysis of acid-soluble fractions of
HSV-1-infected brain tissue and control brain tissue by reversed-phase
HPLC (60 min postinjection).
FIG. 6. Normalized time-activity curves of [18F]FHPG accumula-
tion in the brains of rats in the freeze lesion group, rats in the infected
group, and rats in the control group. The curves were vertically trans-
lated until maximum [18F]FHPG activities were superimposed.
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metabolized and subsequently trapped [18F]FHPG fraction. In
uninfected regions, no metabolites will be formed. Fifteen per-
cent phosphorylation in whole brain homogenates therefore
seems relatively high, considering the fact that this percentage
reflects only those small foci of infection.
During infection with HSV, swelling of the brain vasculature
and tissue occurs. This suggests that during infection of the
brain, the permeability of the blood-brain barrier may be al-
tered (2). Furthermore, the release of chemical mediators such
as bradykinin, arachidonic acid, histamine, and free radicals
can cause an increase in the permeability of the blood-brain
barrier (32). In previous biodistribution studies, we found that
the uptake of [18F]FHPG in brain tissue is approximately
eightfold lower than the level of [18F]FHPG in plasma (14).
This low uptake of [18F]FHPG in the brain reflects the re-
stricted passage through the blood-brain barrier. In the case of
HSV infection, damage to the blood-brain barrier and in-
creased permeability could cause a leakage of [18F]FHPG from
the blood into the brain.
In order to investigate if damage to the blood-brain barrier
itself could also induce a nonspecific elevation of [18F]FHPG
uptake in the brain, we performed freeze lesion experiments. A
freezing injury to the cerebral cortex causes a disruption of the
blood vessels at the site of the lesion, resulting in the move-
ment of edema fluid from the damaged vessels into the extra-
cellular space of the brain parenchyma (3).
The PET data for rats in the freeze lesion group showed an
initial elevated [18F]FHPG uptake compared to that of control
rats. Apparently, the disruption of the blood-brain barrier at
the site of the freeze lesion allows [18F]FHPG to enter the
brain. This was confirmed by brain phosphor storage images of
rats in the freeze lesion group. The tracer uptake was elevated
at the site of the freeze lesion only; there was no distribution of
[18F]FHPG to other brain regions. However, in contrast to the
case for HSV-1-infected brains, the radioactivity in the brains
of rats in the freeze lesion group was rapidly washed out. At 1 h
postinjection, the radioactivity in the brain was still decreasing
and no trapping of radioactivity occurred. In contrast, the
cerebral [18F]FHPG activity in the infected group reached a
plateau and the majority of the radioactivity remained trapped
in the brain, which reflected the trapping of phosphorylated
FHPG metabolites. These differences in kinetics between the
freeze lesion group and the infected group are illustrated in
Fig. 6. The tracer kinetics in the brains of rats in the freeze
lesion group were virtually the same as those for the control
group. The freeze lesion experiments confirmed the fact that
damage to the blood-brain barrier, which usually accompanies
HSE, can initially cause a nonspecific elevation of [18F]FHPG
uptake in the brain by an improved perfusion of brain tissue.
However, this nonspecific tracer uptake can be discriminated
from HSE-derived uptake by the differences in tracer kinetics.
Furthermore, with a freeze lesion, severe damage to the blood-
brain barrier is accomplished. This is probably not comparable
to the mild damage to the blood-brain barrier that can accom-
pany HSE, and therefore our freeze lesion experiments do not
represent ideal control experiments. However, even with this
worst-case scenario, nonspecific [18F]FHPG uptake could be
discriminated from HSE-derived tracer uptake.
In this study, we examined whether encephalitis caused by
HSV could be detected with [18F]FHPG PET. Among the
herpesviruses, HSV is the most frequent causal agent of en-
cephalitis. In patients who are immunosuppressed, encephali-
tis may be caused by other herpesviruses as well, including
varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, and
human herpesvirus 6 (29). All of these viruses encode a viral tk
enzyme and are sensitive to acyclic guanosine-derived antiviral
agents. It can be expected that [18F]FHPG PET could be
applied to detect other herpesviruses besides HSV. Infectious
encephalitis is not only caused by herpesviruses but can also be
due to infections by other viruses, bacteria, rickettsiae, fungi,
or parasites (6). Rocky Mountain spotted fever, for example, is
the most common rickettsial infection in the United States and
may also cause encephalitis (29). Another example is the 1999
outbreak of encephalitis in New York, which was caused by
West Nile virus (24). [18F]FHPG PET should be able to dis-
criminate herpesvirus-derived encephalitis from encephalitis
caused by other infective agents. This is important information
for determining the proper treatment strategy.
The observed phosphorylation of [18F]FHPG provides
“proof of principle” that FHPG accumulation is mediated by
the intracellularly translated tk enzyme of HSV and demon-
strates its diagnostic specificity for herpesvirus-derived enceph-
alitis.
In addition, [18F]FHPG PET might be suitable for deter-
mining ACV’s pharmacokinetics, which could be applied to
predict the efficacy of therapy with ACV, the drug of choice for
treating HSE. Penetration within the cellular compartment
and consecutive phosphorylation of ACV are prerequisites for
the “viricidal” effect. The observation that [18F]FHPG pene-
trates the living brain and is phosphorylated should predict the
same stepwise accumulation of ACV and its effect against the
infection. Whether [18F]FHPG PET could discriminate be-
tween responders and nonresponders at the onset of treatment
remains to be investigated.
There is increasing evidence of a potential viral cause of
Alzheimer’s dementia (17) and psychiatric disorders such as
schizophrenia (25). For this hypothesis to be tested, a nonin-
vasive technique to detect the virus is required. [18F]FHPG
PET could provide a tool to test the hypothesis that a herpes-
virus is the cause of these devastating chronic diseases.
Whether the technique is sufficiently sensitive to detect her-
pesvirus infections in the brains of human patients remains to
be investigated.
We conclude that [18F]FHPG PET appears suitable for
monitoring intracellular herpesvirus infections in the living
brain and may predict the efficacy of consecutive ACV therapy.
[18F]FHPG PET is a promising tool for the diagnosis and
treatment evaluation of HSV encephalitis and, potentially, re-
lated neuropsychiatric disorders.
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